Phase 2 Gene Mutation Clinical Trials
41 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 41 trials
Recruiting
Phase 2
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
GIST - Gastrointestinal Stromal TumorKIT Gene Mutation
Jian Li100 enrolled1 locationNCT07559864
Recruiting
Phase 2
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc90 enrolled35 locationsNCT06995677
Recruiting
Phase 2
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Solid TumorWilms TumorRhabdoid Tumor+4 more
Memorial Sloan Kettering Cancer Center45 enrolled16 locationsNCT05985161
Recruiting
Phase 2
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
NSCLC Stage IVEGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital25 enrolled1 locationNCT07548060
Recruiting
Phase 2
PH 2 Pemigatinib in SDH-deficient GIST
SDH Gene MutationGastrointestinal Stromal Tumor
Dana-Farber Cancer Institute24 enrolled1 locationNCT07434843
Recruiting
Phase 1Phase 2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Phase 2
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Salivary Gland CancerHER2 Gene Mutation
Dana-Farber Cancer Institute37 enrolled13 locationsNCT04620187
Recruiting
Phase 2
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce38 enrolled2 locationsNCT06728410
Recruiting
Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
Alliance for Clinical Trials in Oncology124 enrolled781 locationsNCT02523014
Recruiting
Phase 1Phase 2
Alectinib Pharmacokinetic in Patients With NSCLC
ALK Gene MutationNon-small Cell Lung Cancer Stage IIIB
Instituto Nacional de Cancerologia de Mexico45 enrolled1 locationNCT05713006
Recruiting
Phase 1Phase 2
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
Autosomal Dominant Optic AtrophyOPA1 Gene MutationHereditary Optic Atrophies+1 more
PYC Therapeutics18 enrolled3 locationsNCT06970106
Recruiting
Phase 2
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+21 more
Masonic Cancer Center, University of Minnesota70 enrolled1 locationNCT05735717
Recruiting
Phase 1Phase 2
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Colorectal Cancer (CRC)Metastatic Colorectal Carcinoma (mCRC)Adenomatous Polyposis Coli (APC) Gene Mutation+1 more
HonorHealth Research Institute126 enrolled1 locationNCT07463599
Recruiting
Phase 2
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+12 more
M.D. Anderson Cancer Center60 enrolled1 locationNCT04090567
Recruiting
Phase 2
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaRecurrent Acute Myeloid Leukemia+4 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT03683433
Recruiting
Phase 2
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
PI3K Gene MutationVascular AnomaliesArteriovenous Malformations+11 more
Murdoch Childrens Research Institute50 enrolled2 locationsNCT05983159
Recruiting
Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center63 enrolled3 locationsNCT03383575
Recruiting
Phase 2
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Esophageal CancerGastric AdenocarcinomaHER2 Gene Mutation
Memorial Sloan Kettering Cancer Center49 enrolled10 locationsNCT06123338
Recruiting
Phase 2
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Endometrial CancerRecurrent Endometrial CarcinomaARID1A Gene Mutation
Panagiotis Konstantinopoulos, MD, PhD25 enrolled2 locationsNCT06518564
Recruiting
Phase 2Phase 3
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
PALB2 Gene MutationPancreatic Cancer, Advanced or MetastaticBRCA1/2 Mutation
University Health Network, Toronto10 enrolled1 locationNCT06783140